Literature DB >> 1967959

Highly selective vagotomy 5-15 years on.

I M Macintyre1, A Millar, A N Smith, W P Small.   

Abstract

Highly selective vagotomy for duodenal ulcer was performed on 307 patients between 1973 and 1983 without operative mortality. Of these, 283 (92.2 per cent) were followed up prospectively for a minimum of 5 years. Recurrent ulcer was diagnosed in 49 (17.3 per cent). The recurrent ulcer rate increased from 13.2 per cent at 5 years to 19.4 per cent at 12 years. Age, length of history, previous haemorrhage or perforation and preoperative acid output were not associated with increased risk of recurrent ulceration. The risk in men and smokers was higher but not significantly so. The recurrence rate for individual surgeons varied from 5.3 to 25.6 per cent. Failure of healing with H2-receptor antagonists was not associated with a higher recurrent ulcer rate. Patients with a strong family history (more than one first degree relative affected) had a significantly higher recurrence rate (33.2 per cent at 10 years) than those without (13.5 per cent at 10 years). Of the 49 recurrent ulcer patients, 30 (61.2 per cent) required either an operation or regular H2-receptor antagonists. Of the 250 patients (81.4 per cent) available in 1988 for review of symptoms 5-15 years after operation, 5.4 per cent had dumping, 8.9 per cent epigastric pain, and 11.8 per cent heartburn every day or most days. H2-receptor antagonists were required by 10.7 per cent of patients on a frequent or regular basis. Of 239 patients who answered the question, 218 (91.2 per cent) felt that their symptoms had been cured or greatly improved and 203 (84.9) considered the operation a success. Despite the high recurrence rate, the operation was successful in controlling ulcer symptoms in around 90 per cent of patients and produced postvagotomy symptoms--none severe--in around 5 per cent of patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967959     DOI: 10.1002/bjs.1800770124

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

Review 1.  General surgery.

Authors:  I Taylor
Journal:  Postgrad Med J       Date:  1991-10       Impact factor: 2.401

2.  A requiem for vagotomy.

Authors: 
Journal:  BMJ       Date:  1991-04-06

3.  DNA damage in the stomach after vagotomy measured by 32P-postlabelling.

Authors:  G W Dyke; J L Craven; R Hall; R C Garner
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

4.  Long-term clinical results of highly selective vagotomy performed between 1980 and 1990.

Authors:  M Ihász; J Bátorfi; A Bálint; T Fazekas; M Máté; G Pòsfai; J Sándor
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 5.  Evaluation and management of patients with recurrent peptic ulcer disease after acid-reducing operations: a systematic review.

Authors:  Richard H Turnage; George Sarosi; Byron Cryer; Stuart Spechler; Walter Peterson; Mark Feldman
Journal:  J Gastrointest Surg       Date:  2003 Jul-Aug       Impact factor: 3.452

6.  Twenty years after parietal cell vagotomy or selective vagotomy antrectomy for treatment of duodenal ulcer. Final report.

Authors:  P H Jordan; J Thornby
Journal:  Ann Surg       Date:  1994-09       Impact factor: 12.969

7.  [Results of selective proximal vagotomy after 13 years].

Authors:  F Herbst; E Gruber; T Pratschner; R Schiessel
Journal:  Langenbecks Arch Chir       Date:  1992

8.  Parietal cell vagotomy. A 23-year study.

Authors:  S Meisner; J Hoffmann; H E Jensen
Journal:  Ann Surg       Date:  1994-08       Impact factor: 12.969

Review 9.  Complications associated with ulcer recurrence following gastric surgery for ulcer disease.

Authors:  J G Penston; E J Boyd; K G Wormsley
Journal:  Gastroenterol Jpn       Date:  1992-02

10.  Six-year results of a prospective, randomized trial of selective proximal vagotomy with and without pyloroplasty in the treatment of duodenal, pyloric, and prepyloric ulcers.

Authors:  S Emås; G Grupcev; B Eriksson
Journal:  Ann Surg       Date:  1993-01       Impact factor: 12.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.